Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Cerilliant
Citi
Merck
US Department of Justice
Boehringer Ingelheim
Express Scripts
Argus Health
Farmers Insurance
Daiichi Sankyo

Generated: February 23, 2018

DrugPatentWatch Database Preview

RAPIVAB Drug Profile

« Back to Dashboard

Which patents cover Rapivab, and what generic alternatives are available?

Rapivab is a drug marketed by Biocryst and is included in one NDA. There are three patents protecting this drug.

This drug has fifty-seven patent family members in twenty-seven countries.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the peramivir profile page.
Summary for RAPIVAB
International Patents:57
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 68
Clinical Trials: 2
Patent Applications: 44
Drug Prices:see details
DailyMed Link:RAPIVAB at DailyMed
Drug patent expirations by year for RAPIVAB

US Patents and Regulatory Information for RAPIVAB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocryst RAPIVAB peramivir SOLUTION;IV (INFUSION) 206426-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Biocryst RAPIVAB peramivir SOLUTION;IV (INFUSION) 206426-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Biocryst RAPIVAB peramivir SOLUTION;IV (INFUSION) 206426-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Biocryst RAPIVAB peramivir SOLUTION;IV (INFUSION) 206426-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Biocryst RAPIVAB peramivir SOLUTION;IV (INFUSION) 206426-001 Dec 19, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for RAPIVAB

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,770,427 Antiviral treatments ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for RAPIVAB

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Accenture
US Department of Justice
McKesson
Covington
Cipla
Daiichi Sankyo
Fish and Richardson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot